Ginkgo Bioworks Holdings, Inc. (DNA)
NYSE: DNA · Real-Time Price · USD
9.71
+0.33 (3.52%)
At close: Feb 26, 2026, 4:00 PM EST
8.45
-1.26 (-12.98%)
After-hours: Feb 26, 2026, 7:58 PM EST
Ginkgo Bioworks Holdings Employees
Ginkgo Bioworks Holdings had 834 employees as of December 31, 2024. The number of employees decreased by 384 or -31.53% compared to the previous year.
Employees
834
Change (1Y)
-384
Growth (1Y)
-31.53%
Revenue / Employee
$216,554
Profits / Employee
-$407,129
Market Cap
551.88M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 834 | -384 | -31.53% |
| Dec 31, 2023 | 1,218 | -74 | -5.73% |
| Dec 31, 2022 | 1,292 | 651 | 101.56% |
| Dec 31, 2021 | 641 | 146 | 29.49% |
| Mar 31, 2021 | 495 | - | - |
| Dec 31, 2020 | 495 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| ADC Therapeutics | 265 |
| Neumora Therapeutics | 95 |
| CorMedix | 65 |
| Lexeo Therapeutics | 61 |
| Altimmune | 59 |
| Zevra Therapeutics | 59 |
| Fulcrum Therapeutics | 55 |
DNA News
- 4 hours ago - Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of its Non-Core Biosecurity Business - PRNewsWire
- 7 days ago - Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2025 Results Presentation - PRNewsWire
- 8 days ago - Ginkgo Bioworks and Invaio Sciences Enter Collaboration to Develop Manufacturing Technology for Peptide-based Agricultural Products - PRNewsWire
- 21 days ago - Ginkgo Bioworks' Autonomous Laboratory Driven by OpenAI's GPT-5 Achieves 40% Improvement Over State-of-the-Art Scientific Benchmark - PRNewsWire
- 6 weeks ago - Ginkgo Bioworks Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 2 months ago - Ginkgo Bioworks Partners with Carnegie-Mellon University to Develop Innovative New Cancer Screening Approach - PRNewsWire
- 2 months ago - Ginkgo Bioworks and Agricen Enter Collaboration to Optimize Manufacturing Processes for a Key Agricultural Soil Amendment - PRNewsWire
- 2 months ago - ProteoNic 2G UNic® Technology Licensed by Ginkgo Bioworks for BARDA-Supported Consortium Advancing Monoclonal Antibody Manufacturing for Anti-Filovirus Therapies - GlobeNewsWire